Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
Myocardial ischemia/reperfusion (I/R) injury is a major cause of mortality and morbidity worldwide. Among factors contributing to I/R injury, proteolytic enzymes could also cause cellular injury, expand the injured area and induce inflammation, which then lead to cardiac dysfunction. Therefore, prot...
Main Authors: | Podsawee Mongkolpathumrat, Anusak Kijtawornrat, Eakkapote Prompunt, Aussara Panya, Nipon Chattipakorn, Stephanie Barrère-Lemaire, Sarawut Kumphune |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/4/422 |
Similar Items
-
Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
by: Podsawee Mongkolpathumrat, et al.
Published: (2022-04-01) -
Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury
by: Podsawee Mongkolpathumrat, et al.
Published: (2022-08-01) -
Gelatin-coated silicon oxide nanoparticles encapsulated recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced cardiac cell death against an in vitro simulated ischaemia/reperfusion injury
by: Faprathan Pikwong, et al.
Published: (2023-09-01) -
Secretory Leucoprotease Inhibitor (SLPI) Promotes Survival during Acute <i>Pseudomonas aeruginosa</i> Infection by Suppression of Inflammation Rather Than Microbial Killing
by: Megan Osbourn, et al.
Published: (2022-11-01) -
Recombinant human secretory leukocyte protease inhibitor (rhSLPI) coated titanium enhanced human osteoblast adhesion and differentiation
by: Radchanon Leelasukseree, et al.
Published: (2023-12-01)